Notice Regarding Completion of Business Transfer of Edaravone

Press Release 1/1 April 2, 2026 Notice Regarding Completion of Business Transfer of Edaravone Tanabe Pharma Corporation (Head Office: Osaka, Japan; Representative Director, CEO: Akihisa Harada; hereinafter “Tanabe Pharma”) announces that, as stated in the “Notice Regarding Execution of Transfer the RADICAVA Business” dated December 22, 2025, as of April 1, 2026, all rights—including intellectual property rights and sales rights—in the major countries and regions, including Japan, the United States, and Canada, with respect to edaravone for the treatment of diseases such as amyotrophic lateral sclerosis (ALS) (product name “Radicut” in Japan, “RADICAVA” in the United States), have been transferred to Shionogi & Co., Ltd. (Head office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereinafter “Shionogi”). For certain countries and regions, the rights will be transferred sequentially after completing the prescribed procedures. With this transfer, Tanabe Pharma will strengthen its financial foundation, enabling strategic investment in its clinical pipeline and the creation of new opportunities in line with its future vision. This will encourage reinvestment in the Japanese market and further strengthen our business foundation in Japan through pipeline expansion by partnerships and research and development. Under our MISSION, “Creating hope for all facing illness,” Tanabe Pharma will continue to strive to provide pharmaceuticals that address unmet medical needs, including rare diseases, through in-house development and partnerships with other companies, delivering these options to patients. Contact: Tanabe Pharma Corporation CEO Office Communication Group +81-6-6205-5119

The release as fetched from its publisher. tanabe-pharma.com ↗